Description
Mast cell tumours (MCT) remain a common and occasionally clinically frustrating disease entity in dogs. Recent advances include means to identify patients which may be effectively managed with a lower surgical dose, cytological grading approaches, new molecular tests to potentially add prognostic information, and newer drugs to add to the clinician’s arsenal. This hour will review these advances and frame them in a clinically relevant context.